Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026
Avalyn Pharma announced upcoming presentation of four-year long-term data from their ATLAS open-label extension trial on AP01, an inhaled formulation of pirfenidone, for treating progressive pulmonary fibrosis. The data highlights tolerability and potential to preserve lung function, supporting their Phase 2b clinical development program. Avalyn is…